SAN FRANCISCO, March 5, 2014 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Clifford Baron has a distinguished track record leading product and go to market efforts in prominent life science companies. Most recently, he held the positions of Director of Biology Product Marketing, Director of Business Development and Director of Professional Services at Accelrys, Inc. He founded Lexigraphix, LLC, a strategy consultancy serving biotechnology startups with an innovative web-based system to analyze intellectual property assets. Prior to that entrepreneurial endeavor, Clifford was Senior Director of Global Solutions for Applied Biosystems, Inc. (now part of Life Technologies/Thermo Fisher) where he led software product management and coordinated Applied Biosystems' collaboration with Celera, now part of Quest Diagnostics, Inc. He was Director of Product Management at Pangea Systems / Doubletwist, a pioneering bioinformatics company, and Vice President of Product Development, Product Director and Manager of Technical Products and Information Services for Abacus Concepts, a statistical software company acquired by SAS Corp. Clifford holds a BS in Biology from the University of Washington, and a Ph.D. in Biology from the University of California, Berkeley.
"A market and technology expert in the life sciences software industry, Clifford is ideally suited to lead our continued development and go-to-market strategy for our Genetic Variant Annotation™ Service and our Therapy Finder™ products," said Thomas Mika, President & CEO of CollabRx. "With deep commercial experience in bioinformatics and Next Generation Sequencing, Clifford is the ideal person to take our products and services to the next level. We look forward to having him in a key role on our team."
CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
CONTACT: Thomas R. Mika, CEO CollabRx, Inc. 415-248-5350 or James Carbonara, Regional Vice President Hayden IR 646-755-7412 James@haydenir.com